GP1 and GP2 exhibited increased tumor proliferation (CSNK1D, OPTN, CDK11B, etc.)and immune response (FGB, FGA, FGG, etc.), respectively (Fig. 5E and G), which was presumably related to sensitivity to chemotherapy (including gemcitabine plus cisplatin, gemcitabine, and gemcitabine plus oxaliplatin) and immunotherapy (including pembrolizumab and tislelizumab), respectively (Data S1). Here, CDK11B is linked to neoplasm.